Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Horvath, A; Rainer, F; Bashir, M; Leber, B; Schmerboeck, B; Klymiuk, I; Groselj-Strele, A; Durdevic, M; Freedberg, DE; Abrams, JA; Fickert, P; Stiegler, P; Stadlbauer, V.
Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
Sci Rep. 2019; 9(1):12000-12000 Doi: 10.1038/s41598-019-48352-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Horvath Angela
Rainer Florian
Co-Autor*innen der Med Uni Graz
Bashir Mina
Durdevic Marija
Fickert Peter
Groselj-Strele Andrea
Klymiuk Ingeborg
Leber Bettina
Schmerböck Bianca
Stadlbauer-Köllner Vanessa
Stiegler Philipp

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Proton pump inhibitors (PPI) are an invaluable therapy option for acid related diseases; however, PPI therapy is also linked to a series of side effects in cirrhosis, such as microbiome alterations, spontaneous bacterial peritonitis and hepatic encephalopathy. Decision tools to balance benefits and risks of PPI therapy are largely missing. In this study, we tested gut-derived biomarkers to identify PPI-associated dysbiosis, its association with gut barrier function and liver-related mortality. In this observational study, faecal microbiome composition data obtained from 16S rDNA sequencing of 90 cirrhotic patients with and without long-term PPI use and additional potential biomarkers identified from the literature were evaluated for their predictive value regarding PPI-associated dysbiosis and liver-related three-year mortality. In addition, faecal calprotectin, faecal zonulin and serum lipopolysaccharides were assessed as markers for intestinal inflammation, gut permeability and bacterial translocation. Streptococcus salivarius, Veillonella parvula and the genus Streptococcus were significantly increased in patients with long-term PPI therapy and performed well as biomarkers for PPI-associated dysbiosis (accuracy: 74%, 72% and 74%, respectively). The abundance of Streptococcus salivarius was linked to intestinal inflammation and gut barrier dysfunction, whereas the abundance of Veillonella parvula showed associations with liver disease severity; both were independent predictors for liver-related three-year mortality. Gut-derived biomarkers of PPI-associated dysbiosis are linked to worse outcome and a potential option to evaluate the risks of adverse events during long-term PPI therapy.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Biomarkers -
Dysbiosis - drug therapy
Feces - microbiology
Female -
Gastrointestinal Microbiome - drug effects
Humans -
Intestinal Mucosa - drug effects
Intestinal Mucosa - metabolism
Intestinal Mucosa - microbiology
Liver Cirrhosis - complications
Liver Cirrhosis - etiology
Liver Cirrhosis - mortality
Male -
Middle Aged -
Mortality -
Prognosis -
Proportional Hazards Models -
Proton Pump Inhibitors - administration & dosage
Proton Pump Inhibitors - adverse effects
Treatment Outcome -

© Med Uni Graz Impressum